Neuropharmacology Research Laboratory, Jeffrey Cheah School of Medicine and Health Sciences, Monash University Malaysia, Selangor Darul Ehsan, Malaysia.
Department of Neuroscience, Central Clinical School, The Alfred Hospital, Monash University, Melbourne, Vic., Australia.
CNS Neurosci Ther. 2021 Apr;27(4):381-402. doi: 10.1111/cns.13590. Epub 2021 Feb 4.
Traumatic brain injury (TBI) is the leading cause of death and disability worldwide and has complicated underlying pathophysiology. Numerous TBI animal models have been developed over the past decade to effectively mimic the human TBI pathophysiology. These models are of mostly mammalian origin including rodents and non-human primates. However, the mammalian models demanded higher costs and have lower throughput often limiting the progress in TBI research. Thus, this systematic review aims to discuss the potential benefits of non-mammalian TBI models in terms of their face validity in resembling human TBI. Three databases were searched as follows: PubMed, Scopus, and Embase, for original articles relating to non-mammalian TBI models, published between January 2010 and December 2019. A total of 29 articles were selected based on PRISMA model for critical appraisal. Zebrafish, both larvae and adult, was found to be the most utilized non-mammalian TBI model in the current literature, followed by the fruit fly and roundworm. In conclusion, non-mammalian TBI models have advantages over mammalian models especially for rapid, cost-effective, and reproducible screening of effective treatment strategies and provide an opportunity to expedite the advancement of TBI research.
创伤性脑损伤（TBI）是全球范围内导致死亡和残疾的主要原因，其发病机制复杂。在过去的十年中，已经开发出许多 TBI 动物模型，以有效地模拟人类 TBI 发病机制。这些模型主要来自哺乳动物，包括啮齿动物和非人类灵长类动物。然而，哺乳动物模型需要更高的成本，并且通量较低，这常常限制了 TBI 研究的进展。因此，本系统评价旨在讨论非哺乳动物 TBI 模型在模拟人类 TBI 方面的表面有效性方面的潜在益处。我们在以下三个数据库中搜索了原始文章：PubMed、Scopus 和 Embase，这些文章涉及 2010 年 1 月至 2019 年 12 月发表的非哺乳动物 TBI 模型的原始文章。根据 PRISMA 模型进行了关键性评估，共选择了 29 篇文章。在当前文献中，斑马鱼，包括幼虫和成年鱼，是最常用的非哺乳动物 TBI 模型，其次是果蝇和蛔虫。总之，非哺乳动物 TBI 模型优于哺乳动物模型，特别是在快速、经济高效且可重复筛选有效治疗策略方面，并为加速 TBI 研究提供了机会。
